Physician profile
Benjamin E Studdard
NPI 1588928980
$2,201.88
in general payments reported to CMS, 2019-2025
18 companies · $71.19 in 2025
The $71.19 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $571 · 2021: $526 · 2022: $64.18 · 2023: $79.67 · 2024: $53.98 · 2025: $71.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136 · Education: $69.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $135.77 |
| Education | $69.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $463.74 | 2019-2025 | Lokelma |
| Akebia Therapeutics INC | $352.18 | 2019-2024 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $293.16 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $269.46 | 2019-2025 | Velphoro |
| Opko Pharmaceuticals, LLC | $184.22 | 2019-2021 | |
| Vifor Pharma, INC. | $141.60 | 2019-2021 | |
| Amgen INC. | $108.47 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $76.39 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $72.70 | 2019-2020 | |
| Novo Nordisk INC | $65.02 | 2020-2025 | Wegovy |
| Horizon Therapeutics Plc | $51.99 | 2019-2023 | Krystexxa |
| Baxter Healthcare | $25.89 | 2023 | Gambro - Accute |
| Travere Therapeutics, INC. | $19.85 | 2024-2025 | Filspari |
| Mallinckrodt Enterprises LLC | $18.76 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.72 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15.40 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.22 | 2020 | |
| Genentech USA, INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Studdard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.